About Immunexpress

Immunexpress is developing technology to accurately rule-in or rule-out sepsis in patients suspected of infection.
Lack of reliable diagnostics leads to the over-treatment of sepsis, creating an overwhelming burden to healthcare systems, hospitals, clinicians, nurses, payers and antibiotic stewardship efforts.
Our goal is to transform sepsis diagnostics by providing clinicians with the technology to rapidly enable and confidently make the right treatment decisions.  
   

Immunexpress was founded in Australia in 2006 with the exclusive purpose of developing and commercializing SeptiCyte™ technology. Immunexpress is a privately-owned company with offices in Seattle, USA, and Brisbane, Australia. Immunexpress’ products are based on patented host immune response technologies validated in large human clinical trials around the globe.

Executive Team

Rollie Carlson

Rolland Carlson

CEO – BA, MS, PhD

Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc.

Roy Davis, Chief Medical Officer

Roy Davis

Chief Medical Officer – MD, PhD, MHA

30 years experience – clinical medicine (Neonatal, Pediatric Critical Care) and hospital administration. Clinical Assistant Professor, Department of Pediatrics, University of Washington. Consultant in health care standards and quality of care delivered. CMO at Providence Alaska assisted in the implementation of MEWS and sepsis surveillance algorithms using the Microsoft Amalga platform across Providence Health & Services. Won a national Microsoft Healthcare innovation award for work with MEWS in 2012.

R_Brandon

Richard Brandon

Chief Scientific Officer – BVSc (Hons), PhD, MBA

35 years experience – veterinary immunologist, molecular biologist, pathologist, animal and human healthcare R&D executive: Cornell, Sloan Kettering Cancer Research, University of Queensland, various private pathology laboratories, Genetrax, Plasvacc, BioNiche. Lead author on all Immunexpress patents; architect of IP strategy.

HiRes-Fayyz_Memon-7829-Edit

Fayyaz Memon

Vice President, Regulatory Affairs & Quality – MBA, MS

25 years of experience – in-vitro diagnostics (IVD), medical devices, and pharmaceutical products. Leadership positions at Asuragen, Qiagen, PrimeraDx, Thermo Fisher Scientific, Digene, SmithKline Beecham, and Johnson & Johnson. Founded a regulatory and quality consulting company, AltaQ, with a focus on molecular diagnostics. Completed projects covering multiple countries including the US, China, Japan, France, Germany, and Italy.

Leo McHugh, Director Medical Science Liaison

Leo McHugh

Director, Medical Science Liaison – BSc (Genetics), BSc (Comp Sci), PhD

15 years experience – statistics, epidemiological statistics, biostatistics, machine learning, management, re: complex biological information. VP – R&D and Director Bioinformatics (Immunexpress); Senior Computational Biologist, (Queensland Facility for Advanced Bioinformatics); Westmead Hospital (Sydney); NICTA (Australia’s ICT Research Centre of Excellence).

Greg-Uhl-731x1024

Greg Uhl

Director, Finance - BS (Accounting), MPAcc (Audit and Assurance)

15 years experience – corporate finance, accounting and assurance.  Oversight over GAAP reporting, development of technical accounting policies and ICFR.  Financial Controller (Immunexpress); Controller (GroupAero), Audit Manager (PricewaterhouseCoopers, RSM). Masters of Professional Accounting – University of Washington.

Thomas Yager, Director of Research and Development.jpg

Thomas Yager

Director, Research & Development – BA, MS, PhD

30 years experience. University of Oregon, Weizmann Institute, Kings College London, Hospital for Sick Children (Toronto), and cross-appointment to Dept. Molecular/Medical Genetics, University of Toronto. Broad industry experience in biomarker discovery, development & validation of molecular diagnostic assays; multiple regulatory submissions in USA, Canada and Europe.

Board of Directors

Robert Lilley, Chairman

Robert Lilley

Chairman – BA (Yale)

40 years experience; SVP, Global Sales & Marketing for Digene Corp from IPO to acquisition by QIAGEN NV (in 2007) creating market & technology leader in molecular Dx. Then, Senior Advisor/Molecular Diagnostics for Developing World at QIAGEN. Consultant to John D Rockefeller 3rd Fund, 23andMe, ImpediMed Pty Ltd, Vertex Pharma, OpGen.

Rollie Carlson

Rolland Carlson

CEO – BA, MS, PhD

Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc.

Greg Brown, Non-Executive Director

Greg Brown

Non-Executive Director – BAppSc, MBA

35 years experience – medical devices and in-vitro-diagnostics. International roles for Baxter Diagnostics (Australia & UK), Senior Global Marketing Manager for Roche Molecular Systems, VP Global Strategic Marketing for Digene Corp., and MD for ImpediMed Limited. Presently Chairman & CEO of StraxCorp Pty. Ltd.. Board experience includes: StraxCorp, Minomic, UniQuest, CRC for Diagnostics, Trinity Biotech, Minomic.

Laurie Hammond, Non-Executive Director

Laurie Hammond

Non-Executive Director – BSc, PhD

35 years experience. Start-up investor and Director. Chairman, Commercialisation Australia. Director in Qbator, an early-stage venture fund. Director of, and investor in, several early stage Australian companies in IT and biotech sectors.

Tom Gibbs, Non-Executive Director

Tom Gibbs

Non-Executive Director – BSc, PhD

30 years experience in both start-ups and established companies in Europe and US, including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm. Currently Director at Debiopharm Innovation Fund, Switzerland; responsible for diagnostic investments.

Tanja Dowe, Non-Executive Director

Tanja Dowe

Non-Executive Director – MSc

20 years experience – building business strategies, analyzing markets, strategy & transaction consulting, in- and out-licensing and business acquisitions. CEO of Debiopharm Innovation Fund SA. Managing Partner and Director at Innomedica Ltd., serves on the boards of GenePOC as the chair, Kaiku Health and formerly BC Platforms.

Kathleen Verleysen, Non-Executive Board Member

Katleen Verleysen

Non-Executive Director – MSc, PhD

15 years experience – medical devices and diagnostics. CEO of CellSeeQ, CEO, COO and Vice President of Operations and Technology at Pronota. Founding scientists and Group Leader of Analytical Department at U.S.-based biotech company Serenex, acquired by Pfizer in 2008. Served on boards as chair of the Center for Medical Innovation and PharmaFluidics.